ROBERT T STRIKER, MD PHD
Osteopathic Medicine at Highland Ave, Madison, WI
License number
Wisconsin 43595
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
600 Highland Ave, Madison, WI 53792
Phone
(608) 263-0943
(608) 263-9103 (Fax)
(608) 263-9103 (Fax)
Organization information
See more information about ROBERT T STRIKER at bizstanding.comInfectious Disease Clinic - Dennis G Maki MD
600 Highland Ave #B6-42, Madison, WI 53792
Doing business as:
Infectious Disease Clinic - Robert T Striker MD<br>Infectious Disease Clinic - Bennett S Vogelman MD<br>Infectious Disease - David R Andes MD<br>Infectious Disease Clinic - Andrew W Urban MD
Phone:
(608) 263-0946 (Phone)
Categories:
Infectious Disease Physicians & Surgeons, Physicians & Surgeons, Hematology Physicians & Surgeons
Professional information
Infectious Diseases Staff At Veterans Administration
Location:
Madison, Wisconsin Area
Industry:
Medical Practice
Dr. Robert T Striker, Madison WI - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
1685 Highland Ave STE 5TH, Madison 53705
1685 Highland Ave STE 5TH, Madison 53705
University of Wisconsin Hospital and Clinics
600 Highland Ave, Madison 53792
(608) 263-6400 (Phone), (608) 829-5315 (Fax)
1685 Highland Ave STE 5TH, Madison 53705
University of Wisconsin Hospital and Clinics
600 Highland Ave, Madison 53792
(608) 263-6400 (Phone), (608) 829-5315 (Fax)
Languages:
English
Hospitals:
1685 Highland Ave STE 5TH, Madison 53705
1685 Highland Ave STE 5TH, Madison 53705
University of Wisconsin Hospital and Clinics
600 Highland Ave, Madison 53792
University of Wisconsin Hospitals And Clinics
600 Highland Ave, Madison 53792
1685 Highland Ave STE 5TH, Madison 53705
University of Wisconsin Hospital and Clinics
600 Highland Ave, Madison 53792
University of Wisconsin Hospitals And Clinics
600 Highland Ave, Madison 53792
Education:
Medical School
Washington Univ Sch Of Med
Graduated: 1992
Washington Univ Sch Of Med
Graduated: 1992
Methods And Compositions For Managing Resistance Of Hepatitis C Virus To Immunosuppressant
US Patent:
2010028, Nov 11, 2010
Filed:
Nov 6, 2006
Appl. No.:
11/556925
Inventors:
Robert T. Striker - Madison WI, US
Dan S. Poole - Madison WI, US
Fiona Fernandes - Madison WI, US
Dan S. Poole - Madison WI, US
Fiona Fernandes - Madison WI, US
International Classification:
A61K 38/21, C12Q 1/70, C07H 21/04, C12Q 1/68, A61P 31/12
US Classification:
424 854, 435 5, 536 231, 435 6
Abstract:
Method for determining susceptibility of a hepatitis C virus (HCV) in a patient, especially one who received a liver transplant, to cyclosporine A (CsA), comprising determining the nucleic acid sequence of HCV, and comparing the viral nucleic acid sequence to that of a wild-type, CsA susceptible strain, wherein the existence of at least one mutation in the viral genome is indicative that the virus is resistant to CsA. Also provided are isolated polynucleotide molecules comprising one or more mutations, an array of such molecules, a kit comprising at least one isolated polynucleotide. A method of monitoring the development CsA resistance in a HCV patient, and managing treatment regimens accordingly is further provided. The present invention further provides CsA resistant HCV replicons and method of using them for anti-viral drug screening.
Compositions And Methods For Predicting Hcv Susceptibility To Antiviral Agents
US Patent:
2012007, Mar 29, 2012
Filed:
Sep 9, 2011
Appl. No.:
13/229271
Inventors:
Robert Striker - Madison WI, US
Israr Ansari - Middleton WI, US
Israr Ansari - Middleton WI, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
A61K 38/13, A61P 31/14, C40B 40/08, C12Q 1/70, C07H 21/00
US Classification:
514 43, 435 5, 536 2372, 506 17
Abstract:
Methods for determining the susceptibility of a hepatitis C virus (HCV) in a patient to anti-viral agents, particularly cyclophilin inhibitors such as cyclosporine A, are disclosed. The methods include determining the amino acid sequence within a region of the HCV NS5A protein and comparing the viral amino acid sequence to that of a reference strain, wherein the existence of at least one variant/mutation in the viral genome is indicative that the virus is more or less susceptible to anti-viral agents. Also disclosed are isolated polynucleotide molecules, replicons, and kits that can be used to assay the susceptibility of hepatitis HCV in a patient to anti-viral agents.
2', 3'-Dideoxynucleoside Analogues For The Treatment Or Prevention Of Flaviviridae Infections
US Patent:
2004006, Apr 8, 2004
Filed:
Aug 1, 2003
Appl. No.:
10/632875
Inventors:
Raymond Schinazi - Decatur GA, US
Robert Striker - Madison WI, US
Junxing Shi - Duluth GA, US
Robert Striker - Madison WI, US
Junxing Shi - Duluth GA, US
International Classification:
A61K038/16, A61K031/58, A61K031/7072, A61K031/513
US Classification:
514/008000, 514/269000, 514/050000, 514/176000
Abstract:
A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a -L- or -D-2′,3′-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient.
2', 3'-Dideoxynucleoside Analogues For The Treatment Or Prevention Of Flaviviridae Infections
US Patent:
2008028, Nov 13, 2008
Filed:
Jan 8, 2008
Appl. No.:
11/970908
Inventors:
Raymond F. Schinazi - Decatur GA, US
Junxing Shi - Duluth GA, US
Robert Striker - Madison WI, US
Junxing Shi - Duluth GA, US
Robert Striker - Madison WI, US
Assignee:
Pharmasset, Inc. - Princeton NJ
Emory University - Atlanta GA
Leland Stanford Junior University - Palo Alto CA
Emory University - Atlanta GA
Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 31/70, A61P 31/00
US Classification:
514 44
Abstract:
A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a β-L- or β-D-2′,3′-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient.
Antiviral Agents And Methods Of Use
US Patent:
2005011, Jun 2, 2005
Filed:
Sep 30, 2004
Appl. No.:
10/711681
Inventors:
Robert Striker - Madison WI, US
Adnan Elfarra - Madison WI, US
Sjofn Gunnarsdottir - Madison WI, US
Spencer Hoover - Madison WI, US
Adnan Elfarra - Madison WI, US
Sjofn Gunnarsdottir - Madison WI, US
Spencer Hoover - Madison WI, US
International Classification:
A61K031/522
US Classification:
514263300
Abstract:
The present invention provides therapeutic methods of inhibiting RNA viruses based on the newly-discovered anti-viral activity of cis or trans-6-(2-acetylvinylthio)purine (cis-AVTP) or (trans-AVTP). RNA viruses inhibited by the methods include flaviviruses, namely hepatitis C virus (HCV) and bovine diarrhea virus (BVDV).